MRK | Weekly | Haru Insights

The Phase 3 INTerpath-001 trial results for intismeran autogene demonstrated statistically significant improvements in recurrence-free and distant-metastasis-free survival in high-risk melanoma patients when combined with Keytruda—marking the first pivotal success of an individualized mRNA neoantigen vaccine in oncology.
The trial success triggered a $43 billion market surge for MRK in a single day, fueling a 47% year-to-date stock gain and fundamentally reshaping investor sentiment around MRK’s long-term growth beyond the 2028 Keytruda patent cliff.

MRK has decisively validated a next-generation, platform-based oncology strategy, transforming from a legacy blockbuster-dependent firm into a leader in precision immuno-oncology with scalable potential across lung, bladder, and kidney cancers.
The intismeran-Keytruda combination has become a strategic moat against the looming patent cliff, securing Keytruda’s dominance while establishing MRK as the central architect of a new era in personalized cancer therapy.
MRK’s ability to integrate cutting-edge mRNA technology with its commercial and regulatory prowess positions it uniquely to lead the transition from one-size-fits-all immunotherapy to patient-specific, AI-driven cancer vaccines.
The market’s rapid pricing in future platform success reflects a profound shift in confidence—investors now view MRK not as a defensive dividend play, but as a high-conviction growth engine with multi-decade relevance.
The Phase 3 success marks the first clinical validation of a personalized mRNA vaccine in oncology, a watershed moment that could redefine the standard of care and unlock a new revenue frontier for MRK across multiple solid tumors.

Merck & Co., Inc. (MRK)[Tv]